A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are focused on developing and commercializing products for rare and orphan diseases that have the potential to improve clinical outcomes by using our novel drug delivery technologies. We seek to apply new proprietary formulations to approved and marketed pharmaceutical compounds to achieve enhanced efficacy, faster onset of action, reduced side effects, more convenient drug delivery and increased patient compliance; all of which could result in improved patient outcomes. The active pharmaceutical ingredients used in the drug candidates under development by us may be already approved in a target indication or could be repurposed for use in new indications. Our therapeutic pipeline consists of three unique clinical-stage drug candidates supported by an intellectual property portfolio of more than 40 granted and pending patents in various jurisdictions worldwide.
| Metric | TTM | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | 0 | 100M | 0 | - |
| Net Income | -6.0M | -42M | -9.8M | -20M |
| EPS | $-0.31 | $-34.26 | $-1.62 | $-63.84 |
| Free Cash Flow | 0 | -16M | -17M | -14M |
| ROIC | -32.3% | -62.4% | -9.1% | -35.4% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.00 | 0.01 | 0.00 | 0.00 |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -11M | -52M | -16M | -16M |
| Operating Margin | 0.0% | -52.2% | - | - |
| ROE | -9.2% | -62.4% | -9.1% | -35.4% |
| Shares Outstanding | 15M | 1M | 6M | 1M |
| Metric | 2021 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | N/A | 0 | 100M | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | 4.2M | 5.6M | 10.0M | 3.6M |
| SG&A | 5.5M | 9.3M | 7.6M | 7.6M |
| EBIT | -16M | -16M | -52M | -11M |
| Op. Margin | N/A | N/A | -52.2% | 0.0% |
| Net Income | -20M | -9.8M | -42M | -6.0M |
| Net Margin | N/A | N/A | -42.4% | 0.0% |
| Non-Recurring | 5.7M | 1.6M | 0 | 0 |
| Returns on Capital | ||||
| ROIC | -35.4% | -9.1% | -62.4% | -32.3% |
| ROE | -35.4% | -9.1% | -62.4% | -9.2% |
| ROA | -31.5% | -7.6% | -53.6% | -8.7% |
| Cash Flow | ||||
| Op. Cash Flow | -14M | -17M | -16M | -10M |
| Free Cash Flow | -14M | -17M | -16M | 0 |
| Owner Earnings | -16M | -19M | -18M | -11M |
| CapEx | 69K | 0 | 17K | 0 |
| Maint. CapEx | 924K | 0 | 124K | 7K |
| Growth CapEx | 0 | N/A | 0 | 0 |
| D&A | 924K | 0 | 124K | 7K |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 1.2M | 1.3M | 1.8M | 746K |
| Debt Repayment | 1.6M | 0 | 0 | 0 |
| Balance Sheet | ||||
| Net Debt | -61M | -43M | -27M | -37M |
| Cash & Equiv. | 51M | 30M | 28M | 37M |
| Long-Term Debt | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A |
| Equity | 56M | 108M | 68M | 65M |
| Total Assets | 62M | 129M | 79M | 68M |
| Total Liabilities | 6.8M | 20M | 11M | 3.6M |
| Intangibles | 4.2M | 70M | 41M | 41M |
| Retained Earnings | -146M | -156M | -198M | -227M |
| Working Capital | 61M | 42M | 26M | 18M |
| Current Assets | 62M | 45M | 29M | 19M |
| Current Liabilities | 1.6M | 3.3M | 3.4M | 1.3M |
| Per Share Data | ||||
| EPS | -63.84 | -1.62 | -34.26 | -0.31 |
| Owner EPS | -17.73 | -3.06 | -14.41 | -0.70 |
| Book Value | 60.12 | 17.86 | 54.87 | 4.19 |
| Cash Flow/Share | -15.47 | -2.84 | -12.85 | -0.39 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.9M | 6.1M | 1.2M | 15.5M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -12.3 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | 0.9 |
| Price/Sales | N/A | 0.9 | N/A | N/A |
| FCF Yield | -19.9% | -40.5% | N/A | N/A |
| Market Cap | 72M | 43M | 0 | 59M |
| Avg. Price | 25.13 | 15.35 | 0.00 | 3.82 |
| Year-End Price | 29.28 | 7.02 | 0.00 | 3.82 |
Grace Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Grace Therapeutics, Inc. (GRCE) has a 5-year average return on invested capital (ROIC) of -35.6%. This is below average and may indicate limited pricing power.
Grace Therapeutics, Inc. (GRCE) has a market capitalization of $59M. It is classified as a small-cap stock.
Grace Therapeutics, Inc. (GRCE) does not currently pay a regular dividend.
Grace Therapeutics, Inc. (GRCE) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Grace Therapeutics, Inc. (GRCE) reported annual revenue of $100 million in its most recent fiscal year, based on SEC EDGAR filings.
Grace Therapeutics, Inc. (GRCE) has a net profit margin of -42.4%. The company is currently unprofitable.
Grace Therapeutics, Inc. (GRCE) generated $-16 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Grace Therapeutics, Inc. (GRCE) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
Grace Therapeutics, Inc. (GRCE) reported earnings per share (EPS) of $-34.26 in its most recent fiscal year.
Grace Therapeutics, Inc. (GRCE) has a return on equity (ROE) of -62.4%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Grace Therapeutics, Inc. (GRCE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Grace Therapeutics, Inc. (GRCE) has a book value per share of $54.87, based on its most recent annual SEC filing.